Enhanced cystoscopy at the time of cystectomy and in the outpatient surveillance setting increases detection of high-grade NMIBC.
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
Higher rates of complete response observed in MIBC patients who received a dose-dense combination of methotrexate, vinblastine, doxorubicin, and cisplatin rather than the standard gemcitabine plus cisplatin or carboplatin.
New meta-analysis shows adjuvant intravesical gemcitabine and bacillus Calmette-Guérin do not differ significantly with respect to risk of recurrence, progression, and adverse events.
Among patients undergoing radical cystectomy, female sex is independently associated with a 21% increased odds of surgical site infections compared with male sex.
Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.
British investigators concluded that urine cytology misses a significant number of muscle-invasive bladder cancers.
Recurrence rate was 26.4% among patients who had overnight continuous saline irrigation following transurethral resection of bladder tumor vs 38.2% among those who did not.
The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Bladder preservation for MIBC is associated with a higher mortality rate and greater costs compared with radical cystectomy.
In a randomized study, patients who underwent robotic-assisted and open radical cystectomy had similar 2-year progression survival rates.
Females have worse disease-free, cancer-specific, overall survival versus males with bladder cancer.
In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.
Patients in the highest quintile of urinary albumin excretion had a 4.5-fold increased risk of urothelial cell carcinoma vs those in quintiles 1-3.
Real-world study confirms the improved sensitivity of blue light vs white light cystoscopy (91% vs 79%) for detecting bladder cancer.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
The 5-year overall survival rate is significantly higher among radical cystectomy patients who receive neoadjuvant vs adjuvant chemotherapy, study finds.
Daily use of aspirin before radical cystectomy is associated with a significant 36% and 30% decreased risk of cancer-specific and all-cause mortality.
A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.
Positive results before BCG treatment and at the 6-week instillation are associated with an increased likelihood of disease recurrence and/or progression.
Female sex and need for a blood transfusion are associated with development of Clostridium difficile infection following radical cystectomy.
Large study reveals a significant 15% survival advantage associated with radical cystectomy vs chemoradiation therapy.
Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options.
Enhanced therapeutic effect of bacillus Calmette-Gurin tx in non-muscle invasive bladder cancer.
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Instilling gemcitabine into the bladder immediately following resection of low-grade non-muscle-invasive bladder cancer significantly lowers recurrence risk.
Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
When combined with cytology, UroSEEK detected 95% of patients who developed bladder cancer
Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)